Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Document › Details

Pieris Pharmaceuticals, Inc.. (11/9/16). "Press Release: Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016". Boston, MA.

Organisations Organisation Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
  Organisation 2 Daiichi Sankyo Co., Ltd. (TSE: 4568.JP)
  Group Daiichi Sankyo (Group)
Products Product PRS-080 (Anticalin hepcidin antagonist)
  Product 2 PRS-343 (CD137/HEr2 bispecfic anticalin-based drug, Pieris)
Person Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
     


   
Record changed: 2019-06-09

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for Pieris (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top